Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia

Pegfilgrastim is indicated for reducing the duration of neutropenia and incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy. Here, safety and efficacy of MYL-1401H, a proposed pegfilgrastim biosimilar, were investigated as prophylaxis for chemotherapy-induced neutropenia. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Hematol
Autores principales: Waller, Cornelius F., Ranganna, Gopinath M., Pennella, Eduardo J., Blakeley, Christopher, Bronchud, Miguel H., Mattano Jr, Leonard A., Berzoy, Oleksandr, Voitko, Nataliia, Shparyk, Yaroslav, Lytvyn, Iryna, Rusyn, Andriy, Popov, Vasil, Láng, István, Beckmann, Katrin, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Barve, Abhijit
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469669/
https://ncbi.nlm.nih.gov/pubmed/30824956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-019-03639-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares